BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

709 related articles for article (PubMed ID: 25285170)

  • 1. Functional nanostructures for effective delivery of small interfering RNA therapeutics.
    Hong CA; Nam YS
    Theranostics; 2014; 4(12):1211-32. PubMed ID: 25285170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic siRNA: principles, challenges, and strategies.
    Gavrilov K; Saltzman WM
    Yale J Biol Med; 2012 Jun; 85(2):187-200. PubMed ID: 22737048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo application of RNA interference: from functional genomics to therapeutics.
    Lu PY; Xie F; Woodle MC
    Adv Genet; 2005; 54():117-42. PubMed ID: 16096010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in siRNA delivery in cancer therapy.
    Singh A; Trivedi P; Jain NK
    Artif Cells Nanomed Biotechnol; 2018 Mar; 46(2):274-283. PubMed ID: 28423924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small-interfering RNA (siRNA)-based functional micro- and nanostructures for efficient and selective gene silencing.
    Lee SH; Chung BH; Park TG; Nam YS; Mok H
    Acc Chem Res; 2012 Jul; 45(7):1014-25. PubMed ID: 22413937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor-targeted delivery of siRNA by non-viral vector: safe and effective cancer therapy.
    Chen Y; Huang L
    Expert Opin Drug Deliv; 2008 Dec; 5(12):1301-11. PubMed ID: 19040393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipid Nanoparticle Technology for Clinical Translation of siRNA Therapeutics.
    Kulkarni JA; Witzigmann D; Chen S; Cullis PR; van der Meel R
    Acc Chem Res; 2019 Sep; 52(9):2435-2444. PubMed ID: 31397996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic targeting in the silent era: advances in non-viral siRNA delivery.
    Guo J; Fisher KA; Darcy R; Cryan JF; O'Driscoll C
    Mol Biosyst; 2010 Jul; 6(7):1143-61. PubMed ID: 20431817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy.
    Miele E; Spinelli GP; Miele E; Di Fabrizio E; Ferretti E; Tomao S; Gulino A
    Int J Nanomedicine; 2012; 7():3637-57. PubMed ID: 22915840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity.
    Akhtar S; Benter I
    Adv Drug Deliv Rev; 2007 Mar; 59(2-3):164-82. PubMed ID: 17481774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma.
    Varshosaz J; Farzan M
    World J Gastroenterol; 2015 Nov; 21(42):12022-41. PubMed ID: 26576089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclodextrin-based siRNA delivery nanocarriers: a state-of-the-art review.
    Chaturvedi K; Ganguly K; Kulkarni AR; Kulkarni VH; Nadagouda MN; Rudzinski WE; Aminabhavi TM
    Expert Opin Drug Deliv; 2011 Nov; 8(11):1455-68. PubMed ID: 21867463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strategies for in vivo siRNA delivery in cancer.
    Sanguino A; Lopez-Berestein G; Sood AK
    Mini Rev Med Chem; 2008 Mar; 8(3):248-55. PubMed ID: 18336345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanoparticles for siRNA-Based Gene Silencing in Tumor Therapy.
    Babu A; Muralidharan R; Amreddy N; Mehta M; Munshi A; Ramesh R
    IEEE Trans Nanobioscience; 2016 Dec; 15(8):849-863. PubMed ID: 28092499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hollow Inorganic Nanoparticles as Efficient Carriers for siRNA Delivery: A Comprehensive Review.
    Varshosaz J; Taymouri S
    Curr Pharm Des; 2015; 21(29):4310-28. PubMed ID: 26323421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reducible Dimeric Conjugates of Small Internally Segment Interfering RNA for Efficient Gene Silencing.
    Hong CA; Nam YS
    Macromol Biosci; 2016 Oct; 16(10):1442-1449. PubMed ID: 27273465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Journey of siRNA: Clinical Developments and Targeted Delivery.
    Nikam RR; Gore KR
    Nucleic Acid Ther; 2018 Aug; 28(4):209-224. PubMed ID: 29584585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review of the current status of siRNA nanomedicines in the treatment of cancer.
    Resnier P; Montier T; Mathieu V; Benoit JP; Passirani C
    Biomaterials; 2013 Sep; 34(27):6429-43. PubMed ID: 23727262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current Transport Systems and Clinical Applications for Small Interfering RNA (siRNA) Drugs.
    Liu F; Wang C; Gao Y; Li X; Tian F; Zhang Y; Fu M; Li P; Wang Y; Wang F
    Mol Diagn Ther; 2018 Oct; 22(5):551-569. PubMed ID: 29926308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficient and targeted delivery of siRNA in vivo.
    Shim MS; Kwon YJ
    FEBS J; 2010 Dec; 277(23):4814-27. PubMed ID: 21078116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.